Michael Rosenblatt
Scientist, academic, hospital and global healthcare company executive, Michael Rosenblatt, M.D., is executive vice president and chief medical officer at Merck. He is the company’s primary external advocate on medical issues and the independent voice of the patient inside Merck.
Dr. Rosenblatt previously was Dean of Tufts University School of Medicine; the George R. Minot Professor of Medicine at Harvard Medical School, and president of Beth Israel Deaconess Medical Center (BIDMC). He was the Harvard faculty dean and senior vice president for academic programs at CareGroup and BIDMC. He was also director of the Harvard-MIT Division of Health Sciences and Technology.
Prior to these leadership positions, he was senior vice president for research at Merck where he co-led the worldwide development team for alendronate (FOSAMAX®). Earlier, he was chief of the Endocrine Unit at the Massachusetts General Hospital.
Committed to innovation, he has served on the board of directors and scientific advisory boards of several biotechnology companies and was a scientific founder of ProScript and Radius Pharmaceuticals.
Dr. Rosenblatt was elected to the American Society of Clinical Investigation and the Association of American Physicians, is a fellow of the American Association for the Advancement of Science and the American College of Physicians, and served as the president of the American Society of Bone and Mineral Research.
He received his undergraduate degree summa cum laude from Columbia University and his M.D. magna cum laude from Harvard Medical School.
Dr. Rosenblatt previously was Dean of Tufts University School of Medicine; the George R. Minot Professor of Medicine at Harvard Medical School, and president of Beth Israel Deaconess Medical Center (BIDMC). He was the Harvard faculty dean and senior vice president for academic programs at CareGroup and BIDMC. He was also director of the Harvard-MIT Division of Health Sciences and Technology.
Prior to these leadership positions, he was senior vice president for research at Merck where he co-led the worldwide development team for alendronate (FOSAMAX®). Earlier, he was chief of the Endocrine Unit at the Massachusetts General Hospital.
Committed to innovation, he has served on the board of directors and scientific advisory boards of several biotechnology companies and was a scientific founder of ProScript and Radius Pharmaceuticals.
Dr. Rosenblatt was elected to the American Society of Clinical Investigation and the Association of American Physicians, is a fellow of the American Association for the Advancement of Science and the American College of Physicians, and served as the president of the American Society of Bone and Mineral Research.
He received his undergraduate degree summa cum laude from Columbia University and his M.D. magna cum laude from Harvard Medical School.
Chief Medical Officer, MERCK
-
Share
Related Talks
-
18:44 What if we treated violence like a contagious disease? -
12:48 Can a stitch in time save nine? -
15:34 How did GenX inspire next-gen medical imaging? -
07:44 Don't take life tutu seriously -
20:50 How did a rare disease create the Council of Dads? -
06:22 Does healthcare need a Charles Lindbergh moment?